Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder Post published:December 23, 2021 Post category:Press Release
Numinus Wellness Commends Health Canada on Special Access Programme Amendments to Restore Potential Access to Psychedelic Medicines Post published:December 22, 2021 Post category:Press Release
Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments Post published:December 22, 2021 Post category:Press Release
MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder Post published:December 21, 2021 Post category:Press Release
Optimi Health Receives Dealers License Inspection and Introduces Quality Assurance Department Post published:December 21, 2021 Post category:Press Release
PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022 Post published:December 21, 2021 Post category:Press Release
Lobe Sciences Announces Publication of PCT Patent Application for Its Combination Therapy for mTBI and PTSD Post published:December 21, 2021 Post category:Press Release
Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel Post published:December 21, 2021 Post category:Press Release
HAVN Life Enters into Definitive Agreement to Acquire Spore Life Sciences Inc. Post published:December 20, 2021 Post category:Press Release
Two esteemed doctors join CB Therapeutics in its exploration of innovative approaches to the production of novel psychedelics and cannabinoids so researchers can address the unmet needs of patient communities Post published:December 20, 2021 Post category:Press Release